Sign up USA
Proactive Investors - Run By Investors For Investors

Summit soars as it outlines phase III designs for its C. Diff treatment

The drug developer will design a trial aimed at evaluating the superiority of ridinilazole over the current standard of care C. diff treatment
doctor with a test tube
Two final-stage trials are planned to start in the first half of 2018

Shares in Summit Therapeutics PLC (LON:SUMM; NASDAQ:SMMT) rose sharply after the drug developer outlined plans for the design of the phase III programme for its C. difficile treatment, ridinilazole.

After “constructive” discussions with various regulators including the FDA, Summit said it will design a trial aimed at evaluating the superiority of ridinilazole over the current standard of care C. diff treatment.

“This is something we believe would help differentiate our novel class antibiotic from currently marketed C. difficile treatments and those in late-stage development,” said chief executive Glyn Edwards.

“Superiority in the combined measure of treatment of initial infection and importantly, reduction in recurrence, could position ridinilazole for front-line treatment of C. difficile.”

As Edwards highlighted, a positive phase III result has the potential to support the commercial launch of ridinilazole as a differentiated therapy that can both treat initial C. difficile and reduce disease recurrence.

The phase III programme is expected to include two trials evaluating ridinilazole against the standard of care treatment, vancomycin.

Each trial would enrol around 700 patients with C. difficile, with the primary endpoint being superiority in sustained clinical response (SCR) – an endpoint which measures cure at the end of treatment and a lack of recurrence in the following 30 days.

Other endpoints would include health economic outcome measure, Summit said.

The phase III designs are in-keeping with the successful phase II study, in which ridinilazole achieved “statistical superiority” over vancomycin in SCR.

Summit told investors it hopes to get the trials underway in the first half of next year.

“Our stronger financial position following the DMD programme partnership with Sarepta Therapeutics, Inc. means Summit has more time to fully explore all options,” Edwards added.

“These include potentially entering into a collaboration with a third party or securing meaningful non-dilutive funding from government and charitable organisations.”

Shares were up more than 20%, or 34.5p, on the back of the news to trade at 204.5p.

View full SUMM profile View Profile

Summit Therapeutics PLC Timeline

Related Articles

December 15 2016
The company's nominated adviser said a partnership deal should be signed by the end of 2016
picture of drug research
June 05 2017
With US licensee driving the Phase 1 trials of Sareum's lead candidate, SRA737, the focus moves to TYK2, a compound that is targeting psoriasis, rheumatoid arthritis, and other autoimmune disorders
Proteomics International Laboratories: Access latest PPT from Proactive's CEO Sessions
April 12 2017
Richard Lipscombe talked revenue generation and growth path with investors.
Copyright ©, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use